Pyxis oncology stock prediction.

Pyxis Oncology, Inc. Stock Prediction and Forecast [PYXS]PYXS price prediction was made on Thursday, March 30, 2023. ️ Check the most recent PYXS analysis a...

Pyxis oncology stock prediction. Things To Know About Pyxis oncology stock prediction.

... shares outstanding. -$2.55. CAPs Rating. The percentage of Motley Fool CAPS user ratings that predict this company will outperform the market. Based on ...As of May 13, 2022, the outstanding number of shares of Common Stock of Pyxis Oncology was 32,817,062. About Pyxis Oncology, Inc. Pyxis Oncology, Inc. is a multi-asset multi-modality company focused on defeating difficult to treat cancers and improving patient lives. By leveraging our fully integrated research, development and commercial ...Pyxis Oncology didn't record any revenue over the last year, indicating that it's an early stage company still developing its business. Nonetheless, we can still examine its cash burn trajectory ...Nov 24, 2023 · Price Target Based on short-term price targets offered by four analysts, the average price target for Pyxis Oncology, Inc. comes to $7.25. The forecasts range from a low of $2.00 to a high of... As of September 30, 2023, the outstanding number of shares of common stock of Pyxis Oncology was 44,294,092. About Pyxis Oncology, Inc. Pyxis Oncology, Inc. is a clinical-stage company focused on ...

Aug 15, 2022 · Net loss for the three months ended June 30, 2022 and 2021 included $4.0 million and $0.6 million, respectively, related to non-cash stock-based compensation expense. As of August 15, 2022, the ... Pfizer-backed Pyxis hits 52-week high to cross $200M market cap. Pyxis Oncology ( NASDAQ: PYXS) shares reached a new 52-week high as the clinical-stage biotech backed by pharma giant Pfizer ( PFE ...Pyxis Oncology (PYXS) extended post-market gains Wednesday, adding ~4% in early trading as Pfizer (PFE) raised its ownership in the biotech by more than a third. Read the full story ehre.

Description. Pyxis Oncology Inc is a clinical-stage oncology company focused on developing a multi-modality portfolio of next-generation therapeutics to target difficult-to-treat cancers and improve the quality of life for patients. It develops the product candidates to directly kill tumor cells and address the underlying pathologies created by ...Stock prediction experts have been following Pyxis Oncology closely due to its growth potential. In recent months, BIOT's stock price has been fluctuating but overall, it shows an upward trend. According to some analysts' predictions, BIOT could double or even triple over the next few years if its drug candidates perform well during clinical ...

Pyxis Oncology Inc ( PYXS) is up 1.67% today. PYXS has an Overall Score of 85. Find out what this means to you and get the rest of the rankings on PYXS! PYXS stock closed at $6.00 and is up $0.10 during pre-market trading. Pre-market tends to be more volatile due to significantly lower volume as most investors only trade between …Under the terms of the definitive merger agreement, Pyxis Oncology expects to issue approximately 4.4 million shares of its common stock to Apexigen stockholders to acquire Apexigen. For each share of Apexigen common stock, Pyxis Oncology will issue 0.1725 shares of its common stock, par value $0.001 per share.May 24, 2023 · Under the terms of the definitive merger agreement, Pyxis Oncology expects to issue approximately 4.4 million shares of its common stock to Apexigen stockholders to acquire Apexigen. For each share of Apexigen common stock, Pyxis Oncology will issue 0.1725 shares of its common stock, par value $0.001 per share. As of August 15, 2022, the outstanding number of shares of Common Stock of Pyxis Oncology was 32,834,561. About Pyxis Oncology, Inc. Pyxis Oncology, Inc. is an oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. By leveraging our …Pyxis Oncology has a twelve month low of $1.10 and a twelve month high of $6.92. The business has a fifty day moving average of $1.71 and a 200-day moving average of $2.30. Pyxis Oncology ( NASDAQ:PYXS – Get Free Report) last released its earnings results on Tuesday, November 7th. The company reported ($0.56) earnings per share for …

May 13, 2022 · As of May 13, 2022, the outstanding number of shares of Common Stock of Pyxis Oncology was 32,817,062. About Pyxis Oncology, Inc. Pyxis Oncology, Inc. is a multi-asset multi-modality company ...

Pyxis Oncology, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody, which is in Phase 1 clinical trial for the treatment of solid tumors, …

As of February 13, 2023, the average one-year price target for Pyxis Oncology is $11.22. The forecasts range from a low of $4.04 to a high of $16.80. The average price target represents an ...The stock options have a ten-year term and an exercise price of $4.01, the closing price of Pyxis Oncology’s common stock as reported by Nasdaq on March 31, 2023.As of June 30, 2023, the outstanding number of shares of common stock of Pyxis Oncology was 39,376,941. About Pyxis Oncology, Inc. Pyxis Oncology, Inc. is a clinical-stage company focused on ...Pfizer-backed Pyxis hits 52-week high to cross $200M market cap. Pyxis Oncology ( NASDAQ: PYXS) shares reached a new 52-week high as the clinical-stage biotech backed by pharma giant Pfizer ( PFE ...As of May 10, 2023, the outstanding number of shares of common stock of Pyxis Oncology was 38,245,287. About Pyxis Oncology, Inc. Pyxis Oncology, Inc. is a clinical stage company focused on ...74.38 -1.58(-2.08%) Gold 2,091.70 +34.50(+1.68%) Advertisement Pyxis Oncology, Inc. (PYXS) NasdaqGS - NasdaqGS Real Time Price. Currency in USD Follow 2W 10W 9M 1.6300 +0.0400 (+2.52%) At...

Pyxis Oncology Announces Appointment of Ken Kobayashi, M.D., F.A.C.P as Chief Medical Officer 2023-11-07T16:30:37 Pyxis Oncology Announces Initiatives to Prioritize Lead ADC Program; Reports Financial Results for Third-Quarter 2023 and Provides Corporate UpdatePfizer-backed Pyxis hits 52-week high to cross $200M market cap. Pyxis Oncology ( NASDAQ: PYXS) shares reached a new 52-week high as the clinical-stage biotech backed by pharma giant Pfizer ( PFE ...See Pyxis Oncology, Inc. stock price prediction for 1 year made by analysts and compare it to price changes over time to develop a better trading strategy. As of September 30, 2023, the outstanding number of shares of common stock of Pyxis Oncology was 44,294,092. About Pyxis Oncology, Inc. Pyxis Oncology, Inc. is a clinical-stage company focused on ...Find the latest analyst research for Pyxis Oncology, Inc. Common Stock (PYXS) at Nasdaq.com. Pyxis Oncology has initiated dosing with PYX-201 in a phase 1 study, with preliminary results due in early 2024. ... PYXS trades very cheaply and an argument could be made for entering the stock ...Pyxis Oncology expects to issue 4 million of PYXS stock to fuel its purchase of Apexigen. When the deal closes, it will result in current APGN shareholders owning 10% of the combined company.

Mar 22, 2023 · Full-Year 2022 Financial Results. As of December 31, 2022, Pyxis Oncology had cash and cash equivalents (including restricted cash) of $180.7 million, which is expected to fund operations into the ...

Pyxis Oncology issued approximately 4.3 million shares of common stock as a result of this transaction, and immediately post-acquisition, Pyxis Oncology is expected to have 43,872,248 shares of ...Nov 30, 2023 · The current price Pyxis Oncology ( PYXS) is trading at is $1.51, which is within the analyst’s predicted range. Browse analyst ratings and price targets on all stocks. Analysts publish ratings ... According to analysts, Pyxis Oncology's stock has a predicted upside of 311.52% based on their 12-month stock forecasts. What analysts cover Pyxis Oncology? Pyxis Oncology has been rated by HC Wainwright , Royal Bank of Canada , and William Blair in the past 90 days.Pyxis Oncology Inc (NASDAQ: PYXS) agreed to acquire Apexigen Inc (NASDAQ: APGN) in an all-stock transaction for an implied value of $0.64 per Apexigen share. Apexigen went public in a blank-check ...Buy. Initiates. $19. +809.09%. Nov 2, 2021. A list of analyst ratings for Pyxis Oncology (PYXS) stock. See upgrades, downgrades, price targets and more from top Wall Street stock analysts.Find the latest Pyxis Oncology Inc (PYXS) stock forecast, 12-month price target, predictions and analyst recommendations.Based on Pyxis Oncology’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $38 thousand and a GAAP net loss of $19.24 million.Pyxis Oncology, Inc. (PYXS) Stock Price, Quote & News - Stock Analysis 1.55 +0.15 (10.71%) At close: Nov 24, 2023, 1:00 PM 1.43 -0.12 (-7.74%) After-hours: …Pyxis Oncology, Inc. (NasdaqGS:PYXS) completed the acquisition of Apexigen, Inc. (NasdaqCM:APGN) from entities associated with Pfizer Inc. (NYSE:PFE), …Nastassia Samal. Pfizer ( PFE) backed Pyxis Oncology ( NASDAQ: PYXS) is acquiring Apexigen ( NASDAQ: APGN) in an all stock deal, for a total enterprise value of ~$16M. Under the agreement, Pyxis ...

For each share of Apexigen common stock, Pyxis Oncology will issue 0.1725 shares of its common stock, par value $0.001 per share. Upon closing of this business combination, Apexigen will become a ...

BOSTON, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company focused on developing next-generation therapeutics to target difficult-to-treat cancers ...

Nov 30, 2023 · Pyxis Oncology has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings. Price Target Upside/Downside. According to analysts' consensus price target of $8.33, Pyxis Oncology has a forecasted upside of 411.2% from its current price of $1.63. Nov 30, 2023 · The current price Pyxis Oncology ( PYXS) is trading at is $1.51, which is within the analyst’s predicted range. Browse analyst ratings and price targets on all stocks. Analysts publish ratings ... Net loss for the three months ended June 30, 2022 and 2021 included $4.0 million and $0.6 million, respectively, related to non-cash stock-based compensation expense. As of August 15, 2022, the ...Wall Street Stock Market & Finance report, prediction for the future: You'll find the Predictive Oncology share forecasts, stock quote and buy / sell signals below. According to present data Predictive Oncology's POAI shares and potentially its market environment have been in a bullish cycle in the last 12 months (if exists).ZIM Integrated Shipping Services (NYSE:ZIM) pays an annual dividend of $9.35 per share and currently has a dividend yield of 134.73%. ZIM has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. Read our dividend analysis for ZIM.As of September 30, 2023, the outstanding number of shares of common stock of Pyxis Oncology was 44,294,092. About Pyxis Oncology, Inc. Pyxis Oncology, Inc. is a clinical-stage company focused on ...Full-Year 2022 Financial Results. As of December 31, 2022, Pyxis Oncology had cash and cash equivalents (including restricted cash) of $180.7 million, which is expected to fund operations into the ...Nov 29, 2023 · See the latest Pyxis Oncology Inc stock price (PYXS:XNAS), related news, valuation, dividends and more to help you make your investing decisions. Sep 27, 2023 · Our pipeline. We are focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve the quality of life of patients. We have built a broad portfolio of clinical assets, including novel ADC and mAb product candidates that we are developing as monotherapies and in combination with other therapies. Based on Pyxis Oncology’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $38 thousand and a GAAP net loss of $19.24 million.BOSTON, May 11, 2023 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company focused on developing next-generation therapeutics to target difficult-to-treat cancers, today reported financial results for the quarter ended March 31, 2023, and provided a corporate update. Pyxis Oncology ended the first quarter of 2023 ...

Mar 30, 2023 · Pfizer-backed Pyxis hits 52-week high to cross $200M market cap. Pyxis Oncology ( NASDAQ: PYXS) shares reached a new 52-week high as the clinical-stage biotech backed by pharma giant Pfizer ( PFE ... Sep 27, 2023 · BOSTON, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company focused on developing next-generation therapeutics to target difficult-to-treat cancers ... KURA: Get the latest Kura Oncology stock price and detailed information including KURA news, historical charts and realtime prices. Indices Commodities Currencies StocksInstagram:https://instagram. click away santa cruz cagld returnssetting up a trust account for real estatemerrill edge hidden fees Pyxis Oncology has assembled a differentiated portfolio of clinical assets, including antibody-drug conjugates (ADCs) and monoclonal antibody (mAb) … shopify stock newstaxes for day trading Pyxis Oncology, Inc. is a clinical stage company focused on defeating difficult-to-treat cancers. The company is efficiently building next-generation therapeutics that hold the potential for mono ... best forex trading books Nov 7, 2023 · Pyxis Oncology stock was originally listed at a price of $13.20 in Oct 8, 2021. If you had invested in Pyxis Oncology stock at $13.20, your return over the last 2 years would have been -86.82%, for an annualized return of -63.69% (not including any dividends or dividend reinvestments). — Pyxis Oncology to host webcast with Key Opinion Leaders (KOLs) on April 27, 2021 at 1:00pm ET — CAMBRIDGE, Mass., April 27, 2021 – Pyxis Oncology (“Pyxis” or the “Company”) today announced the targets of its three antibody-drug conjugate (ADC) candidates along with additional details and preclinical data supporting the …